Clinical trial
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue…
NCT00070109 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00070109 |
|---|---|
| Title | Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors |
| Official title | A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor |
| Intervention type | Drug, Other |
| Interventions | trabectedin, pharmacological study |
| Enrollment | 50 |
| Start date | Jan 1, 2008 |
| Primary completion | Oct 1, 2010 |
| Completion | Dec 1, 2013 |
| First posted | Oct 7, 2003 |
| Last update posted | Sep 14, 2018 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: